Management of small cell lung cancer: Recent developments for optimal care

Drugs

Volumn 72, Issue 4, 2012, Pages 471-490

  Califano, Raffaele ^a   Abidin, Aidalena Z ^a   Peck, Rahul ^a   Faivre Finn, Corinne ^a   Lorigan, Paul ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Amrubicin; Anthracyclines; Bevacizumab; Breast cancer; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Gefitinib; Gemcitabine; Imatinib; Interferon alpha; Irinotecan; Lung cancer; Pemetrexed; Picoplatin; Radiotherapy; Small cell lung cancer; Thalidomide; Topotecan; Trastuzumab; Vincristine

Indexed keywords

AMRUBICIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FIGITUMUMAB; GANITUMAB; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; PEMETREXED; PICOPLATIN; PLACEBO; RILOTUMUMAB; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COGNITION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; QUALITY OF LIFE; RASH; REVIEW; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; SMALL CELL LUNG CARCINOMA;

EID: 84857338470     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11597640-000000000-00000     Document Type: Review

References (120)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006 Oct 1; 24 (28): 4539-44 (Pubitemid 46630948)
3. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007 Dec; 2 (12): 1067-77 (Pubitemid 350307898)
4. Cheng S, EvansWK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007 Apr; 2 (4): 348-54 (Pubitemid 47181720)
5. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 Dec 1; 24 (34): 5441-7 (Pubitemid 46623178)
6. Sculier JP, Lafitte JJ, Lecomte J, et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002 Sep; 13 (9): 1454-9
7. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 Feb; 17 (2): 658-67 (Pubitemid 29075255)
8. O'Bryan RM, Crowley JJ, Kim PN, et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990 Feb 15; 65 (4): 856-60 (Pubitemid 20063484)
9. Giaccone G, DonadioM, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988 Aug; 6 (8): 1264-70
10. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987 Oct; 107 (4): 451-8 (Pubitemid 17149757)
11. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991 Jun 19; 83 (12): 855-61
12. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992 Feb; 10 (2): 282-91
13. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999 Jun; 17 (6): 1794-801 (Pubitemid 29269249)
14. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000 Jul; 83 (1): 8-15
15. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002 Dec 15; 20 (24): 4665-72 (Pubitemid 36025283)
16. Baka S, Califano R, Ferraldeschi R, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008 Aug 5; 99 (3): 442-7
17. Amarasena IU, Walters JA, Wood-Baker R, et al. Platinumversus non-platinumchemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008 (4): CD006849
18. Sorensen M, Pijls-Johannesma M, Felip E, Group ObotEGW. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May 1; 21 Suppl. 5: v120-5
19. Simon GR, Turrisi A. Management of small cell lung cancer. Chest 2007 Sep 1; 132 (3 Suppl.): 324-39S
20. Johnson BE, Crawford J, Downey RJ, et al. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2006 Jul; 4 (6): 602-22 (Pubitemid 44265467)
21. Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988 Mar; 6 (3): 451-6 (Pubitemid 18090691)
22. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989 Apr; 59 (4): 578-83 (Pubitemid 19111749)
23. Johnson D, Bass D, Einhorn L, et al. Combination chemotherapy with or without thoracic radiotherapy in limitedstage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993 Jul 1; 11 (7): 1223-9 (Pubitemid 23199123)
24. Bozcuk H, Artac M, Ozdogan M, et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? Cancer 2005; 104 (12): 2650-7
25. Rossi A, GarassinoMC, CinquiniM, et al.Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70 (2): 119-28
26. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992 Aug 1; 10 (8): 1225-9
27. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998 Mar 1; 16 (3): 1068-74 (Pubitemid 28108742)
28. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 Jan 10; 346 (2): 85-91 (Pubitemid 34438898)
29. Hanna N, Bunn Jr PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensivestage disease small-cell lung cancer. J Clin Oncol 2006 May 1; 24 (13): 2038-43 (Pubitemid 46622112)
30. Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 May 20; 27 (15): 2530-5
31. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998 Jul 7; 95 (14): 8170-4 (Pubitemid 28326085)
32. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010 Sep 1; 21 (9): 1810-6
33. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008 Sep 10; 26 (26): 4261-7
34. Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011 Aug; 22 (8): 1798-804
35. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010; 5 (6): 867-73
36. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 1994 Mar 1; 5 (3): 283-5
37. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003 Apr 15; 21 (8): 1550-5 (Pubitemid 46594109)
38. Pallis AG, Agelidou A, Agelaki S, et al. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer 2009 Aug; 65 (2): 187-91
39. van der Lee I, Smit EF, van Putten JWG, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001 Apr 1; 12 (4): 557-61 (Pubitemid 32472114)
40. Schuette W, Nagel S, Juergens S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005 Sep; 7 (2): 133-7 (Pubitemid 43192130)
41. Rocha-Lima C, Herndon J, Lee M, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 2007 Feb 1; 18 (2): 331-7 (Pubitemid 46323102)
42. Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 2009 Jan; 64 (1): 75-80
43. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006 Oct 20; 24 (30): 4840-7 (Pubitemid 46630910)
44. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009 Oct 1; 27 (28): 4787-92
45. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008 Feb 15; 14 (4): 1059-64 (Pubitemid 351302551)
46. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensivedisease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Investigational New Drugs 2007; 25 (3): 253-8 (Pubitemid 46774694)
47. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study0301. J Clin Oncol 2006 Dec 1; 24 (34): 5448-53 (Pubitemid 46623179)
48. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as secondline treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011 Jan 20; 29 (3): 287-93
49. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinumrefractory small-cell lung cancer. J Clin Oncol 2010; 28 (15): 2598-603
50. Jotte R, Von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as secondline treatment for small cell lung cancer (SCLC). ASCO Meeting Abstracts 2011 Jun 9; 29 (15 Suppl.): 7000
51. Kobayashi M, Matsui K, Iwamoto Y, et al. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer. West Japan Thoracic Oncology Group Study 0301. J Thoracic Oncol 2010; 5 (7): 1075-80
52. O'Brien M, Jassem J, Lorigan P, et al. Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): 7052
53. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study0301. J Clin Oncol 2006 Dec 1; 24 (34): 5448-53 (Pubitemid 46623179)
54. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008 Nov 20; 26 (33): 5401-6
55. Kato T, Nokihara H, Ohe Y, et al. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC) [abstract no. 7061]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I; 2006 Jun 20; 24 (18 Suppl.): 7061
56. Kawamura-Akiyama Y, Kusaba H, Kanzawa F, et al. Non-cross resistance of ZD0473 in acquired cisplatinresistant lung cancer cell lines. Lung Cancer 2002; 38 (1): 43-50 (Pubitemid 35299991)
57. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009 Apr 20; 27 (12): 2046-51
58. Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best suppor-tive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy [abstract no. 7002]. J Clin Oncol 2010 Jun; 28 (15 Suppl.)
59. Blay J-Y, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010; 116 (22): 5126-37
60. Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004; 31 (2 Suppl. 4): 20-5 (Pubitemid 38609789)
61. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10): 947-57
62. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 Jun 30; 364 (26): 2507-16
63. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003 Dec 1; 9 (16 Pt 1): 5880-7 (Pubitemid 38018071)
64. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005 May 15; 103 (10): 2128-31 (Pubitemid 40605121)
65. Schneider BJ, Gadgeel S, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 17089
66. Johnson FM, Krug LM, Tran HT, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006 Jan 15; 106 (2): 366-74 (Pubitemid 43100446)
67. Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006 Apr; 52 (1): 93-7 (Pubitemid 43340205)
68. Macaulay VM, Everard MJ, Teale JD, et al. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res 1990 Apr 15; 50 (8): 2511-7 (Pubitemid 20134519)
69. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004 May; 3 (5): 527-35 (Pubitemid 39193731)
70. Lorigan P, Soria J, Stephenson J, et al. Safety and pharmacokinetics of first-line AMG 479 (mab to IGF1R) or AMG 102 (mab to HGF?SF) with platinum-based chemotherapy in extensive stage small cell lung cancer (SCLC). Ann Oncol 2010 Jun; 21 Suppl. 8: viii122-61
71. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003 Oct 1; 63 (19): 6272-81 (Pubitemid 37255174)
72. Amgen Inc. A phase 1b/2 trial of AMG 479 or AMG102 in combination with platinum-based chemotherapy as firstline treatment for extensive stage small cell lung cancer [ClinicalTrials.gov identifier NCT00791154]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 4]
73. Pujol JL, Breton JL, Gervais R, et al. Phase III doubleblind, placebo-controlled study of thalidomide in extensivedisease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007 Sep 1; 25 (25): 3945-51 (Pubitemid 47477272)
74. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009 Aug 5; 101 (15): 1049-57
75. Patton JF, Spigel DR, Greco FA, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 7085
76. Spigel DR, Hainsworth JD, Farley C, et al. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol 2008 May 20; 26 (15 Suppl.): 7554
77. Sarah Cannon Research Institute. Irinotecan, carboplatin, bevacizumab, and radiation therapy in the treatment of limited stage small cell lung cancer [ClinicalTrials.gov identifier NCT00308529]. US National Institutes of Health, ClincalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 4]
78. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). ASCO Meeting Abstracts 2007 Jun 21; 25 (18 Suppl.): 7563
79. Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009; 4 (12): 1555-60
80. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensivestage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011 Jun 1; 29 (16): 2215-22
81. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009 Dec 10; 27 (35): 6006-11
82. Ramalingam SS, Mack PC, Vokes EE, et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study (NCI # 7097). J Clin Oncol 2008 May 20; 26 (15 Suppl.): 8078
83. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007 Sep 20; 25 (27): 4278-84 (Pubitemid 47548568)
84. Hoosier Oncology Group. Cisplatin and etoposide +-concurrent vandetanib in previously untreated extensive stage small cell lung cancer [ClinicalTrials.gov iden-tifier NCT00613626]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 4]
85. Gitlitz BJ, Glisson BS, Moon J, et al. Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial. J Clin Oncol 2008 May 20; 26 (15 Suppl.): 8039
86. Park Nicollet Institute. Phase I study of weekly topotecan in combination with sorafenib in treatment of relapsed small cell lung cancer [ClinicalTrials.gov identifier NCT00466232]. US National Institutes of Health, Clin icalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2012 Jan 4]
87. Southwest Oncology Group. Sorafenib in treating patients with extensive stage small cell lung cancer [ClinicalTrials. gov identifier NCT00182689]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 4]
88. Leach JW, Swenson K, Anderson E, et al. A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC). ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): e18086
89. Ready N, Dunphy F, Pang H, et al. Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): 7056
90. Lubiner ET, Spigel DR, Greco FA, et al. Phase II study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer. ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): 7049
91. Schneider BJ, Gadgeel SM, Ramnath N, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC). ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): e18041
92. Yan JJ, Chen FF, Tsai YC, et al. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 1996 Jan-Feb; 53 (1): 6-11
93. Jiang SX, Kameya T, Sato Y, et al. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996 Mar; 148 (3): 837-46 (Pubitemid 126660675)
94. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensivestage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008 Feb 20; 26 (6): 870-6 (Pubitemid 351398078)
95. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008 Apr 1; 68 (7): 2321-8 (Pubitemid 351521806)
96. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008 Jun 1; 14 (11): 3268-77
97. Gandhi L, CamidgeDR,Ribeiro de OliveiraM, et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011Mar 1; 29 (7): 909-16
98. Fossella F, Woll P, Lorigan P, et al. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). 13th World Conference on Lung Cancer; 2009 Jul 31-Aug 4; San Francisco (CA)
99. Woll PJ, O'Brien M, Fossella F, et al. Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol 2010 Oct 1; 21 Suppl. 8: viii175
100. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006 Feb 1; 12 (3 Pt 1): 878-87 (Pubitemid 43259871)
101. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003 Aug 1; 63 (15): 4441-9 (Pubitemid 36951016)
102. H. Lee Moffitt Cancer Center and Research Institute. Vaccine therapy and chemotherapy with or without tretinoin in treating patients with extensive-stage small cell lung cancer [ClinicalTrials.gov identifier NCT00618891]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 5]
103. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008 Sep 15; 22 (18): 2454-72
104. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422 (6929): 313-7 (Pubitemid 36378358)
105. Eastern Cooperative Oncology Group. Cisplatin and etoposide phosphatewith orwithoutGDC-0449 or cixutumumab in treating patients with extensive-stage small cell lung cancer [ClinicalTrials.gov identifier NCT00887159]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 5]
106. Infinity Pharmaceuticals, Inc. A phase 1 study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies [ClinicalTrials.gov identifier NCT00761696]. US National Institutes of Health,ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 5]
107. Bayman NA, Sheikh H, Kularatne B, et al. Radiotherapy for small-cell lung cancer: where are we heading? Lung Cancer 2009; 63 (3): 307-14
108. Turrisi 3rd AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999 Jan 28; 340 (4): 265-71 (Pubitemid 29063268)
109. De Ruysscher D, Pijls-Johannesma M, Bentzen Sr M, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006 Mar 1; 24 (7): 1057-63 (Pubitemid 46638802)
110. Baas P, Belderbos JSA, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involvedfield radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer 2006; 94 (5): 625-30 (Pubitemid 43361891)
111. De Ruysscher D, Bremer R-H, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 2006; 80 (3): 307-12 (Pubitemid 44397204)
112. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of 18FDG-PET scans in limiteddisease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77 (2): 329-36
113. Auperin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl JMed 1999; 341 (7): 476-84 (Pubitemid 29372887)
114. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10 (5): 467-74
115. Le Péchoux C, Laplanche A, Faivre-Finn C, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 2011 May; 22 (5): 1154-63
116. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007 Aug 16; 357 (7): 664-72 (Pubitemid 47267236)
117. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms, results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol 2009 Jan 1; 27 (1): 78-84
118. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999 Jul 1; 17 (7): 2092-9 (Pubitemid 29318840)
119. VU University Medical Center, Department of Radiation Oncology. Randomised trial on chest irradiation in extensive disease small cell lung cancer. Nederlands Trial Register identifier NTR1527 [online]. Available from URL: http://www.trialregister.nl/trialreg/admin/rctview. asp?TC=1527 [Accessed 2012 Jan 26]
120. Gore E. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC) [online]. Available from URL: http://www.rtog.org/Clin icalTrials/ ProtocolTable/StudyDetails.aspx?study=0937 [Accessed 2012 Jan 26]